SCHEMBL6415263

SCHEMBL6415263

Nc1nc2nonc2nc1NN=Cc1ccc(-c2cccc([N+](=O)[O-])c2)o1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 14/20 0.64
MEN1 O00255 10/20 0.64
KMT2A Q03164 10/20 0.64
HTT P42858 3/20 0.64
ALDH1A1 P00352 2/20 0.57
LMNA P02545 1/20 0.57
HPGD P15428 1/20 0.57
ALOX12 P18054 1/20 0.57
NPSR1 Q6W5P4 1/20 0.57
L3MBTL1 Q9Y468 2/20 0.56
SMN1; SMN2 Q16637 1/20 0.56
MAPK1 P28482 2/20 0.53
RAB9A P51151 2/20 0.51
POLB P06746 1/20 0.51
CTDSP1 Q9GZU7 1/20 0.51
SAE1 Q9UBE0 1/20 0.51
UBA2 Q9UBT2 1/20 0.51
TDP1 Q9NUW8 1/20 0.51
MCL1 Q07820 2/20 0.50
BIRC5 O15392 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6436712 0.86 MAPT (0.57) MAPTMEN1KMT2AHTTALDH1A1
SCHEMBL6436709 0.86 MAPT (0.57) MAPTMEN1KMT2AHTTALDH1A1
SCHEMBL6438200 0.84 MAPT (0.52) MAPTMEN1KMT2AHTTALDH1A1
SCHEMBL6438197 0.84 MAPT (0.52) MAPTMEN1KMT2AHTTALDH1A1
SCHEMBL6414077 0.84 MAPT (0.53) MAPTMEN1KMT2AHTTALDH1A1
SCHEMBL6414075 0.84 MAPT (0.53) MAPTMEN1KMT2AHTTALDH1A1
SCHEMBL6507696 0.84 MAPT (0.52) MAPTMEN1KMT2AHTTALDH1A1
SCHEMBL6507700 0.84 MAPT (0.52) MAPTMEN1KMT2AHTTALDH1A1
SCHEMBL6438174 0.84 MAPT (0.51) MAPTMEN1KMT2AHTTALDH1A1
SCHEMBL6438176 0.84 MAPT (0.51) MAPTMEN1KMT2AHTTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050143382-A1 Heterocyclic compounds as pharmaceutically active compounds 4SC AG (DE) 2005-06-30 US disclosed
EP-1529531-A1 Oxadiazolopyrazine derivatives as pharmaceutically active compounds 4SC AG (DE) 2005-05-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050143382-A1 Heterocyclic compounds as pharmaceutically active compounds NR5A2, NR1H2, NR2C2 MAPT 4420/4885MEN1 4392/4885KMT2A 3640/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.